Updated:
Alloy Therapeutics
Alloy Therapeutics was founded by bioengineer and serial entrepreneur Tillman Gerngross, who previously co-founded venture-backed biotechs including...
Alloy Therapeutics
Alloy Therapeutics was founded by bioengineer and serial entrepreneur Tillman Gerngross, who previously co-founded venture-backed biotechs including Adimab and Alector. The Waltham, Massachusetts-based firm is structured as a collaborative discovery partner, not a traditional biotech, and channels all profits back into platform R&D. Its leadership includes President Errik Anderson — a co-inventor on more than 40 patent families from prior roles at Compass Therapeutics and Adimab — and Alasdair Thong, who runs the Sovereign Innovation Division after investing stints at Index Ventures and Mubadala Capital. The firm deploys capital into an integrated antibody and genetic-medicines discovery platform that covers antibody and bispecific engineering, TCR-mimic discovery via its Keyway platform, antisense oligonucleotide design using the Anticlastic format, and cell therapy development. Its computational biology team, led by the CEO of the Insights Division in Basel, trains predictive models on proprietary experimental datasets to shorten design cycles. Alloy maintains a physical footprint across five sites: a high-velocity antibody discovery unit in Athens, Georgia, a transgenic platform team in Cambridge, UK, the computational group in Basel, and a cell therapy development arm that originated from the Takeda-Kyoto University iPS CAR-T platform in Fujisawa, Japan. Alloy’s 100-plus scientists have supported over 200 partners, though the firm does not report assets under management. In May 2026, it presented AI/ML-driven discovery workflows at PEGS Boston. Adjacent structures include Spannerwerks, a venture-building arm, and the Sovereign Innovation Division, which pursues ecosystem-level biotech investments. The executive team is anchored by Heather Cochenour, who joined from Verseau Therapeutics to manage strategic alliances as Chief Business Officer and Head of Antibodies. Alloy differs structurally from a conventional CRO or venture studio. It operates as a pre-competitive infrastructure layer: partners pay for access to discovery services and platform technologies, and the firm reinvests all surplus into expanding its modality coverage and computational tools. This architecture avoids the asset-centric royalty model that creates conflicts with partners, instead scaling through a service-and-ecosystem flywheel under Gerngross’s chairmanship.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Additional offices
Athens, GA · Cambridge, UK · Basel, Switzerland · Fujisawa, Japan
Principals
Tillman Gerngross
Founder, CEO, Chairman
Errik Anderson
President
Heather Cochenour
CBO, Head of Antibodies and Strategic Collaborations
Alasdair Thong
CEO, Sovereign Innovation Division
Sector focus
Frequently asked questions
Who runs investment and operational decisions at Alloy Therapeutics?
Tillman Gerngross serves as Founder, CEO, and Chairman, setting strategic direction and overseeing the firm's reinvestment model. Errik Anderson, as President, manages translational science and platform development, reflecting his 25-year research career and co-inventorship of over 40 patent families (per the firm's leadership page). Division-level autonomy sits with CEOs who run antibody, genetic-medicines, cell therapy, and computational-insight units.
How does Alloy Therapeutics fund its platform expansion and avoid royalty conflicts?
Alloy explicitly states that 100% of its profits are reinvested into future innovation, a structure that replaces traditional royalty stacking with a service-fee model. This means partners pay for discovery services and platform access, and the firm does not compete with them for downstream asset economics. The model is designed to align incentives across a broad partner base.
What modalities does Alloy Therapeutics cover, and where are the capabilities physically located?
The firm integrates six major modalities: antibodies and bispecifics, TCR mimics (Keyway platform), genetic medicines including antisense oligonucleotides (Anticlastic format), and cell therapies. Capabilities are distributed globally — antibody discovery runs through Waltham, MA, and Athens, GA; transgenic platform development sits in Cambridge, UK; computational biology and AI/ML modeling operate out of Basel, Switzerland; and the cell therapy arm was built on the Takeda-Kyoto University iPS CAR-T platform in Fujisawa, Japan.
Is Alloy Therapeutics structured as a single family office or does it operate more like a venture firm?
Alloy is a private, for-profit company structured as a collaborative discovery platform, not a family office or a traditional venture capital firm. It earns revenue through partner-funded discovery services and platform licensing, and it contains adjacent venture-building arms like Spannerwerks and the Sovereign Innovation Division, which pursue ecosystem investments.
Does Alloy Therapeutics participate in fund commitments or only direct service partnerships?
Alloy's core model centers on direct, fee-for-service partnerships and technology platform access; it is not an institutional limited partner. The Sovereign Innovation Division, however, invests in life science ventures, and Spannerwerks operates as a venture builder, indicating the firm allocates its own reinvested capital to both internal platform expansion and external biotech formation.
What is Alloy's relationship to Adimab and other Gerngross-founded biotechs?
Tillman Gerngross founded Adimab as an antibody discovery platform company prior to starting Alloy Therapeutics. While Adimab focused on yeast-based antibody optimization, Alloy was built as a broader, multi-modality pre-competitive engine. Gerngross also co-founded Alector, Arsanis, and Compass Therapeutics, and several Alloy executives, including Errik Anderson, previously held leadership roles at Adimab and Compass, bringing that translational expertise into Alloy's collaborative model.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: